Pacira BioSciences, Inc.
$ 25.58
2.85%
06 Aug - close price
- Market Cap 991,365,000 USD
- Current Price $ 25.58
- High / Low $ 25.72 / 24.70
- Stock P/E 191.31
- Book Value 16.63
- EPS 0.13
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.01 %
- ROE 0.01 %
- 52 Week High 27.66
- 52 Week Low 18.80
About
Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare professionals and their patients in the United States. The company is headquartered in Parsippany, New Jersey.
Analyst Target Price
$29.83
Quarterly Earnings
| Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-08-04 | 2026-04-30 | 2026-02-26 | 2025-11-06 | 2025-08-05 | 2025-05-08 | 2025-02-27 | 2024-11-06 | 2024-07-30 | 2024-05-07 | 2024-02-29 | 2023-11-02 |
| Reported EPS | 0.44 | 0.6 | 0.32 | 0.7 | 0.74 | 0.62 | 0.91 | 0.79 | 0.89 | 0.62 | 0.89 | 0.72 |
| Estimated EPS | 0.27 | 0.56 | 0.6 | 0.65 | 0.71 | 0.6 | 0.8303 | 0.7 | 0.7 | 0.62 | 0.87 | 0.78 |
| Surprise | 0.17 | 0.04 | -0.28 | 0.05 | 0.03 | 0.02 | 0.0797 | 0.09 | 0.19 | 0 | 0.02 | -0.06 |
| Surprise Percentage | 62.963% | 7.1429% | -46.6667% | 7.6923% | 4.2254% | 3.3333% | 9.5989% | 12.8571% | 27.1429% | 0% | 2.2989% | -7.6923% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: PCRX
2026-08-06 11:41:15
Pacira BioSciences announced the publication of positive two-year results from its Phase 1 clinical trial for PCRX-201, an investigational gene therapy for knee osteoarthritis, in the Annals of the Rheumatic Diseases. The study found that a single intra-articular injection of PCRX-201 was well-tolerated and showed improvements in pain, stiffness, and function for up to two years. The company is advancing PCRX-201 into its Phase 2 ASCEND trial, with initial topline data expected by year-end 2026.
2026-08-05 19:41:15
Pacira BioSciences (PCRX) has advanced its osteoarthritis gene therapy candidate, PCRX-201, to a scalable U.S. commercial manufacturing process and has begun enrolling patients in Part B of the Phase 2 ASCEND study. The company's shares are currently trading at US$26.92, which is significantly below its narrative fair value of $38.00, suggesting it is undervalued. Despite a 52.07% decline in total shareholder return over five years, the past year has shown improving momentum with a 19.43% return.
2026-08-05 19:41:15
Pacira BioSciences (PCRX) reported strong second-quarter 2026 results, beating analyst estimates for both earnings and revenues, driven by demand for Exparel, Zilretta, and iovera. Despite the strong performance, the company cut its 2026 sales outlook due to the divestiture of iovera, while maintaining other financial guidance. Pacira also secured a major win with UnitedHealthcare providing separate reimbursement for Exparel, expanding its covered lives.
2026-08-05 19:41:15
Pacira BioSciences reported a 6% increase in Q2 2026 revenue to $192.4 million, driven by strong sales of EXPAREL, ZILRETTA, and iovera°. The company highlighted expanded payer coverage for EXPAREL and progress in its pipeline, while also completing the sale of iovera° to Zimmer Biomet. Pacira updated its full-year revenue guidance to reflect the divestiture but maintained its EXPAREL sales outlook, emphasizing growth from outpatient settings and commercial reimbursement.
2026-08-05 12:42:11
RBC has increased its price target for Pacira Biosciences (PCRX) to $25 from $24, while maintaining a Sector Perform rating on the stock. This adjustment comes shortly after Pacira BioSciences reported its Q2 2026 earnings, posting an adjusted EPS of $0.73 per share against an estimated $0.65, and revenue of $192.4 million, exceeding the FactSet estimate of $191.1 million. The company also updated its earnings guidance for the full year 2026.
2026-08-05 08:42:11
Pacira BioSciences reported its Q2 2026 earnings, highlighting a 6% increase in total revenue to $192.4 million, driven by EXPAREL, ZILRETTA, and iovera° sales growth. The company successfully divested iovera° to Zimmer Biomet and lowered its full-year 2026 revenue guidance to $735 million-$760 million. Pacira emphasized strategic partnerships, pipeline advancements, and expanded commercial payer coverage for EXPAREL, including UnitedHealthcare, as key drivers for future growth despite a slowdown in certain elective soft tissue procedures.
